FME.DE - Fresenius Medical Care AG & Co. KGaA
| Previous Close | 85.50 |
| Open | 85.16 |
| Bid | 0.00 x 38700 |
| Ask | 0.00 x 105300 |
| Day's Range | 84.94 - 86.18 |
| 52 Week Range | 77.22 - 93.82 |
| Volume | 452,015 |
| Avg. Volume | 564,201 |
| Market Cap | 26.217B |
| Beta | 0.62 |
| PE Ratio (TTM) | 13.34 |
| EPS (TTM) | 6.42 |
| Earnings Date | Oct 30, 2018 |
| Forward Dividend & Yield | 1.06 (1.25%) |
| Ex-Dividend Date | 2018-05-18 |
| 1y Target Est | 93.55 |
- Simply Wall St.•17 hours ago
Has Fresenius Medical Care AG & Co KGaA’s (ETR:FME) Earnings Momentum Changed Recently?
In this article, I will take a look at Fresenius Medical Care AG & Co KGaA’s (ETR:FME) most recent earnings update (30 June 2018) and compare these latest figures againstRead More...
- Motley Fool•3 days ago
3 Reasons Cara Therapeutics Is a Great Pick for Aggressive Investors
This biotech could deliver big returns for investors who aren't afraid of taking on considerable risk.
- Motley Fool•11 days ago
NxStage Just Got This Vital Lifeline
Here's the good news the dialysis specialist needed.
- Thomson Reuters StreetEvents•15 days ago
Edited Transcript of FME.DE earnings conference call or presentation 31-Jul-18 1:30pm GMT
Q2 2018 Fresenius Medical Care AG & Co KGaA Earnings Call
- Zacks•21 days ago
Fresenius Medical (FMS) Misses Q2 Earnings & Sales Estimates
Lower peritoneal dialysis sales in Q2 hurt Fresenius Medical (FMS); solid geographical performance encourages.
- Motley Fool•last month
The Picture for Cara Therapeutics Just Got Clearer
A significant amount of the risk for this little biotech has been addressed.
- The Wall Street Journal•2 months ago
[$$] Fresenius Medical Sells Sound Inpatient Physicians for $2.15 Billion
Fresenius Medical Care AG said it completed the divestment of Sound Inpatient Physicians Holdings, selling the business to an investment consortium led by Summit Partners. The German company, which provides dialysis services, said the divestment will bolster its net income by about $752 million.
- Zacks•2 months ago
Here's Why You Should Steer Clear of Fresenius Medical Now
Soft segmental performance and a downbeat revenue guidance reflect Fresenius Medical's (FMS) weaknesses.
- Simply Wall St.•2 months ago
Is Fresenius Medical Care AG & Co KGaA (ETR:FME) A Buy At Its Current PE Ratio?
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to better understand how you canRead More...
- Reuters•2 months ago
FMC takes stake in Humacyte in bet on bioengineered blood vessel
Germany's Fresenius Medical Care (FMC) (FMEG.DE) has agreed to take a $150 million (112.3 million pounds) stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval. The world's largest provider of kidney dialysis, FMC is banking on the alliance to lead to better ways of accessing patients' blood vessels, a delicate medical procedure that is part of providing life-saving dialysis, the company said in a statement on Monday. FMC will take a 19 percent stake in the privately held company.
- American City Business Journals•2 months ago
Durham’s Humacyte lands $150M from Fresenius Medical Care
Durham-based Humacyte has landed a $150 million equity investment from Fresenius Medical Care. According to the companies, the investment will see Fresenius (NYSE: FMS) take a 19 percent fully diluted ownership stake in Humacyte and obtain the exclusive global rights to commercialize Humacyte’s human acellular vessel Humacyl upon approval by certain health authorities. “Humacyte is at this true inflection point in the development of our blood vessel,” says Humacyte Chief Medical Officer Dr. Jeff Lawson.
- PR Newswire•2 months ago
Fresenius Medical Care and Humacyte announce strategic global partnership supported by a $150M equity investment
BOSTON, June 11, 2018 /PRNewswire/ -- Fresenius Medical Care, the world's largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, today announced a strategic, global partnership and a $150M USD equity investment. This agreement has the potential to make Humacyte's investigational human acellular vessel, HUMACYL®, available to more patients worldwide following approval of the product. HUMACYL is currently being investigated for vascular access for hemodialysis and may prove more effective than current synthetic grafts and fistula.
- Moody's•2 months ago
Ironman Merger Sub, LLC -- Moody's assigns B1 CFR to Ironman Merger Sub, LLC (aka Sound Inpatient Physician Holdings, LLC)
Moody's Investors Service (Moody's) assigned a B1 Corporate Family Rating (CFR) and B1-PD Probability of Default Rating to Ironman Merger Sub, LLC. Ironman Merger Sub, LLC will become Sound Inpatient Physician Holdings, LLC ("Sound") immediately following the $2.2 billion acquisition of the company. Sound will be acquired by Summit Partners and OptumHealth Holdings, LLC ("OptumHealth") from Fresenius Medical Care AG & Co. KGaA (Baa3 stable). OptumHealth is owned by health insurance company UnitedHealth Group, Inc. (A3 stable).
- Motley Fool•3 months ago
Why Cara Therapeutics Shares Jumped 10% Today
Investor optimism continues following an important licensing deal earlier in the week.
- Motley Fool•3 months ago
Does This New Partnership Make Cara Therapeutics Stock a Buy Now?
A new deal with a major dialysis provider could propel Korsuva much further than expected.
- Benzinga•3 months ago
Cara Therapeutics Shares Jump On Licensing Deal For Pruritis Treatment
Cara said it has licensed worldwide rights — except in the U.S., Japan and South Korea — to commercialize Korsuva injection with VFMCRP, a joint venture between Vifor Pharma and Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS). The deal provides for a $50-million upfront cash payment to Cara and an equity investment of $20 million via share sales at $17 apiece.
- Zacks•3 months ago
Here's Why You Should Sell Fresenius Medical (FMS) Stock Now
A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).
- Motley Fool•3 months ago
NxStage Keeps Losing Money as Key Deadline Grows Nearer
Find out why concerns about the dialysis specialist's merger are getting worse.
- Simply Wall St.•3 months ago
Are Fresenius Medical Care AG & Co KGaA’s (ETR:FME) Interest Costs Too High?
Investors pursuing a solid, dependable stock investment can often be led to Fresenius Medical Care AG & Co KGaA (XTRA:FME), a large-cap worth €26.04B. Risk-averse investors who are attracted toRead More...
- Zacks•3 months ago
Fresenius Medical (FMS) Misses on Q1 Earnings, Lowers View
Lackluster performance in North America and foreign exchange headwinds mar Fresenius Medical's (FMS) bottom line in Q1.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of FME.DE earnings conference call or presentation 3-May-18 1:30pm GMT
Q1 2018 Fresenius Medical Care AG & Co KGaA Earnings Call
- Motley Fool•4 months ago
Here's Why Akorn Inc Fell as Much as 16.4% Today
Investors received new details explaining why Fresenius dropped its acquisition. They aren't good.
- PR Newswire•4 months ago
RenalSense Announces Distribution Agreement With Fresenius Medical Care
JERUSALEM , April 30, 2018 /PRNewswire/ -- RenalSense® has entered into an agreement with Fresenius Medical Care (Bad Homburg) for distribution of its Clarity RMS® critical care urine monitoring system ...
- Zacks•4 months ago
The Zacks Analyst Blog Highlights: ArcelorMittal, Fresenius Medical Care AG, Orion Engineered Carbons S.A., Royal Dutch Shell and Globant S.A.
The Zacks Analyst Blog Highlights: ArcelorMittal, Fresenius Medical Care AG, Orion Engineered Carbons S.A., Royal Dutch Shell and Globant S.A.
